BAY 80-6946 (Copanlisib) Chemical Properties

Density 

1.51

storage temp. 

Store at -20°C

solubility 

insoluble in DMSO; insoluble in H2O; insoluble in EtOH

form 

solid

pka

8.42±0.20(Predicted)

color 

Off-white to light brown

BAY 80-6946 (Copanlisib) Usage And Synthesis

Binding Mode

As shown in the co-crystal structure of copanlisib bound to PI3Kγ, the inhibitor binds with only one critical hydrogen bond to the amide NH of Val882 in the adenine pocket, employing the imidazoline N1 nitrogen (Figs. 1 and 2). In addition, the C5 aminopyrimidine group fills the affinity pocket, forming hydrogen bonds with two carboxylic residues of Asp836 and Asp841 through the amino group. Finally, the solvent exposed morpholine lies over Trp812, presumably providing additional attractive molecular contacts.

Uses

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.

Definition

ChEBI: Copanlisib is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of morpholines, an aromatic ether, a diether, a tertiary amino compound, a secondary carboxamide, a pyrimidinecarboxamide, an aminopyrimidine and an imidazoquinazoline.

brand name

Aliqopa

General Description

Class: lipid kinase; Treatment: FL (IV infusion); Other name: BAY 80-6946; Elimination half-life = 52 h (IV); Protein binding = 84.2%

Pharmacokinetics

Copanlisib has poor oral bioavailability due to low permeability and poor solubility, and therefore, it is not suitable for an oral medication. Consequently, it was developed as an IV drug. IV infusion of copanlisib resulted in rapid distribution throughout the body and a prolonged elimination half-life (52 h).

target

pan-PI3K

Metabolism

Copanlisib was the predominant component in human plasma, accounting for 84% of total radioactivity AUC, and the morpholinone metabolite 6 was the only circulating metabolite (about 5%).

BAY 80-6946 (Copanlisib)(1032568-63-0)Related Product Information

• Salirasib
• BKM120 (NVP-BKM120, Buparlisib)
• Alpelisib (BYL719)
• Pictilisib
• IPI 145
• CAL-101
• BEZ235 (NVP-BEZ235, Dactolisib)